These include the “c-myc transcription factor targets upregulated” (brain, leukemia, lung), the “RAS oncogenic pathway signature” (brain, lung, kidney) and the “G-protein signaling, coupled to cAMP” (“colon, ovary, kidney”). This evidence concerns the gene MYC and leukemia.